Patient Guide: HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 182 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05338970
Status: ACTIVE_NOT_RECRUITING
Condition: Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Phase: PHASE3

Where You Can Participate

This study is available at 182 locations across the country.

Top locations include:
  • • Anchorage, Alaska
  • • Springdale, Arkansas
  • • Duarte, California
  • • And 179 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy - Join Clinical Trial NCTNCT05338970

How to Join This Clinical Trial - NCTNCT05338970

Learn how to participate in this PHASE3 trial studying an investigational therapy for Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT05338970 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 182 locations. Find a study site near you:

Clinical Research Site

Anchorage, Alaska 99508 - United States

Status: Contact for availability

Clinical Research Site

Springdale, Arkansas 72762 - United States

Status: Contact for availability

Clinical Research Site

Duarte, California 91010 - United States

Status: Contact for availability

Clinical Research Site

La Jolla, California 92037 - United States

Status: Contact for availability

Clinical Research Site

La Jolla, California 92037 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90033 - United States

Status: Contact for availability

Clinical Research Site

Vallejo, California 94589 - United States

Status: Contact for availability

Clinical Research Site

Whittier, California 90603 - United States

Status: Contact for availability

Clinical Research Site

Port Charlotte, Florida 33980 - United States

Status: Contact for availability

Clinical Research Site

Atlanta, Georgia 30322 - United States

Status: Contact for availability

And 172 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships